Company / SG&A Expense
Fulgent Genetics, Inc. SG&A Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$116.7M
FY2025
5-year range
$6.4M / $116.7M
FY2021-FY2025
Trend
+32.4%
vs FY2024
Sector context
#130 of 158
Health Care
What the data says
Fulgent Genetics, Inc.'s sg&a expense of $117M is lower than 82% of companies in the Health Care sector (FY2025). SG&A Expense has increased for 4 consecutive years, from $6M in FY2021 to $117M in FY2025.
Based on SEC 10-K filings.
$117M in FY2025 with a 5-year CAGR of +50.3%.
Increased from $51M to $117M over the past 2 years.
Health Care sector context is included.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- +97.2%
- 5-Year CAGR
- +50.3%
- 10-Year CAGR
- -
Sector benchmark
Top 18% in Health CareTop 18% of 158This company $116.7M Sector average $175.9B
▼
-99.9% below sector average
Key checks
Key Insights
- Fulgent Genetics, Inc.'s sg&a expense has grown for 4 consecutive years.
- 5-year CAGR of +50.3%, indicating consistent growth.
- In FY2025, sg&a expense increased 32.4% year-over-year.
- Ranks #130 out of 158 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 5.28 (safe zone, above 2.9 threshold)
- Negative profit margin: -15.1%
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $116.7M | +32.4% |
| FY2024 | $88.1M | +73.7% |
| FY2023 | $50.7M | +233.4% |
| FY2022 | $15.2M | +137.2% |
| FY2021 | $6.4M | -57.8% |
| FY2020 | $15.2M | +174.7% |
| FY2019 | $5.5M | +5.8% |
| FY2018 | $5.2M | +0.0% |
| FY2017 | $5.2M | +2175.2% |
| FY2016 | $230.0K | -90.5% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026